I know Wayne does not like giving sporadic updates to the market, but I think (providing that the news is positive) the market/share price would benefit from an update prior to the end of the financial year.
should cover the below;
- Planned changes to business structure if any (regarding immunotherapies)
- ADAPT sales, a high level commentary on whether the company have seen the performance they were expecting so far in Q4 etc plus details re Vascucel, NEO and 3D....
- Budget for next year. They would have completed this by now, possibly subject to Board approval.
Clear these things up and people will have the transparency they need to make an informed investment decision.
IMO
"Take a Closer Look", page-980
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$9.80 |
Change
0.020(0.20%) |
Mkt cap ! $207.1M | |||
| Open | High | Low | Value | Volume |
| $9.85 | $10.78 | $9.60 | $572.9K | 57.96K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 5627 | $9.80 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $10.00 | 931 | 1 |
View Market Depth
| Last trade - 16.10pm 19/11/2024 (20 minute delay) ? |
| AVR (ASX) Chart |